Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo 
Welcome,         Profile    Billing    Logout  
 71 Diseases   11 Trials   11 Trials   468 News 
14 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zevalin (ibritumomab tiuxetan) / Servier, Aurobindo
FIL FLAZ12, NCT01827605 / 2012-000251-14: A Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)

Active, not recruiting
3
159
Europe
ZEVALIN, RIT, BEAM, ASCT
Fondazione Italiana Linfomi - ETS
Relapsed Follicular Lymphoma
10/19
01/24
NCT02320292: Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Completed
3
20
US
Quality-of-Life Assessment, Quality of Life Assessment, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima, Yttrium Y-90 Ibritumomab Tiuxetan, IDEC-Y2B8, IDEC-Y2B8 monoclonal antibody, Y 90 Ibritumomab Tiuxetan, Y 90 Zevalin, Yttrium Y 90 Ibritumomab Tiuxetan, yttrium Y90 ibritumomab tiuxetan
Mayo Clinic, National Cancer Institute (NCI)
Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma
02/21
11/23
2004-004349-16: Targeted Intensification by a new preparative regimen for patients with Low-Grade B-Cell Lymphoma utilizing standard dose Ytrium 90 Ibritumomab Tiuxetan (Zevalin) radioimmunotherapy (RIT) combined with high dose BEAM followed by autologous stem cell transplantation (ASCT)

Ongoing
2
75
Europe
Ibritumomab tiuxetan, Yttrium-90, CARMUSTINE, Mabthera, Aracytine, Alkeran, Etoposide, Ro45 2994, Kit for radiopharmaceutical preparation, Radiopharmaceutical precursor, Powder and solvent for solution for injection, Concentrate for solution for infusion, Powder and solvent for solution for infusion, Solution for infusion, Zevalin, Ytracis, BCNU, Mabthera100mg, Mabthera500mg, Aracytine, Alkeran, VP16
GELA Group
Low grade B-cell lymphoma CD20 positive:-Marginal zone-Lymphocytic-Follicular
 
 
2012-001768-31: ZENO-01 90Y ibritumomab tiuxetan in patients with extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) ZENO-01 90Y IBRITUMOMAB TIUXETANO IN PAZIENTI CON LINFOMA A CELLULE B DELLA ZONA MARGINALE EXTRANODALE DEL TESSUTO LINFOIDE ASSOCIATO ALLA MUCOSA (LINFOMA MALT)

Ongoing
2
20
Europe
Powder and solvent for solution for infusion, ZEVALIN*INFUS 1F 2ML 1,6MG/ML
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI, Spectrum pharmaceuticals, Irvine , California
MALT Lymphoma LINFOMA MALT, extra-nodal marginal zone B-cell lymphoma of Mucosa associated lymphoid tissue (MALT Lymphoma) LINFOMA A CELLULE B DELLA ZONA MARGINALE EXTRANODALE DEL TESSUTO LINFOIDE ASSOCIATO ALLA MUCOSA (LINFOMA MALT), Diseases [C] - Cancer [C04]
 
 
2006-006808-11: Phase II study of 90Y ibritumomab tiuxetan (Zevalin) in patients with untreated follicular non-Hodgkin\'s lymphoma.

Ongoing
2
50
Europe
ZEVALIN, ZEVALIN
AZIENDA OSPEDALIERA UNIVERSITARIA SAN MARTINO GENOVA
Patients with untreated follicular non-Hodgkin\'s lymphoma grade 1 or 2 according to REAL classification.
 
 
2006-004851-39: A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDYTO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENTTREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN)IN ELDERLY ( 60 YEARS) PATIENTS WITH DIFFUSE LARGE BCELLLYMPHOMA AFTER 4 CYCLES OF CHOP21 ﾖRITUXIMAB(CHOP21-R) THERAPY.

Ongoing
2
55
Europe
ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG, ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
DIFFUSE LARGE BCELLLYMPHOMA
 
 
2006-004850-26: A phase II, open-label, prospective, multicenter study to evaluate theefficacy and safety of subsequent treatment with the Zevalin(ibritumomab tiuxetan) study in patients with follicular grade I-IIlymphoma after 4 cycles of Fludarabine-Mitoxantrone-Rituximab(FMR) therapy.

Ongoing
2
55
Europe
ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG, ZEVALIN*INFUS 1F 3ML 1,6MG/ML, MABTHERA*EV 2F 10ML 100MG
AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
follicular grade I-IIlymphoma
 
 
2005-003796-20: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg)90Y-ibritumomab tiuxetan (\"Zevalin\") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (HOVON 77)

Ongoing
2
12
Europe
Mabthera, Zevalin, Mabthera, Zevalin
HOVON Foundation
patients with diffuse Large B-Cell lymphoma, CD20-positive
 
 
2007-000699-18: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI

Ongoing
2
222
Europe
PREDNISONE, RITUXIMAB, DOXORUBICINE, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, METHOTREXATE, G-CSF, VINCRISTINE, IFOSFAMIDE, ETOPOSIDE, CYTARABINE, CARMUSTINE, MELPHALAN, autologous stem cells, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN
Hospices Civils de Lyon, Groupe d\'Etude des Lymphomes de l\'Adulte(GELA)
CD20+ diffuse large B-cell lymphoma
 
 
2006-007083-28: Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with R-PECC chemotherapy.

Ongoing
2
60
Europe
prednisone, chlorambucil, etoposide, lomustine, 90Y-ibritumomab tiuxetan, A07EA03, Mabthera, Zevalin, Mabthera, Zevalin
HOVON foundation, KWF, Spectrum Pharmaceuticals
Aggressive B-cell NHL
 
 
2009-012944-17: Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (“Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-PET and on stem cell mobilisation. A Phase II clinical trial.

Ongoing
2
31
Europe
90Y-ibritumomab tiuxetan, rituximab, prednisone, cyclophosphamide, vincristine, A07EA03, Zevalin, Mabthera, mabthera, Zevalin, Mabthera, mabthera
VUMC
follicular B cell NHL
 
 
NCT00577278: A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan

Checkmark P2 data - 1st line fNHL
Jun 2012 - Jun 2012: P2 data - 1st line fNHL
Completed
2
41
US
rituximab, IDEC-C2B8, IDEC-C2B8 monoclonal antibody, Mabthera, MOAB IDEC-C2B8, Rituxan, fludarabine phosphate, 2-F-ara-AMP, Beneflur, Fludara, melphalan, Alkeran, CB-3025, L-PAM, L-phenylalanine mustard, L-Sarcolysin, sirolimus, AY 22989, Rapamune, rapamycin, SLM, tacrolimus, FK 506, Prograf, allogeneic hematopoietic stem cell transplantation, indium In 111 ibritumomab tiuxetan, IDEC-In2B8, yttrium Y 90 ibritumomab tiuxetan, 90Y ibritumomab tiuxetan, IDEC Y2B8, Y90 Zevalin, Y90-labeled ibritumomab tiuxetan, laboratory biomarker analysis
City of Hope Medical Center, National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia, Lymphoma
05/19
12/23
NCT01359592: S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Completed
2
159
US
rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, R-CHOP regimen, laboratory biomarker analysis, fludeoxyglucose F 18, selective external radiation therapy, yttrium Y 90 ibritumomab tiuxetan
SWOG Cancer Research Network, National Cancer Institute (NCI)
Lymphoma
06/20
12/23
NCT01811368: Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Active, not recruiting
2
20
US
rituximab, IDEC-C2B8, Mabthera, Rituxan, ibritumomab tiuxetan, Zevalin, anti-thymocyte globulin, ATG, ATGAM, lymphocyte immune globulin, Thymoglobulin, total nodal irradiation, TLI, total lymphoid irradiation, peripheral blood stem cell transplantation, PBPC transplantation, PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell, allogeneic hematopoietic stem cell transplantation, cyclosporine, cyclosporin, cyclosporin A, CYSP, Sandimmune, mycophenolate mofetil, Cellcept, MMF
Joseph Tuscano, Spectrum Pharmaceuticals, Inc
Refractory Non Hodgkin Lymphoma, Relapsed Non Hodgkin Lymphoma
04/23
12/23

Download Options